$41.75
0.53% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Structure Therapeutics Stock price

$41.75
+0.68 1.66% 1M
-1.16 2.70% 6M
+0.99 2.43% YTD
+6.05 16.95% 1Y
+26.75 178.33% 3Y
+26.75 178.33% 5Y
+26.75 178.33% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.22 0.53%
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Key metrics

Market capitalization $2.38b
Enterprise Value $1.45b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.58
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-122.59m
Free Cash Flow (TTM) Free Cash Flow $-105.58m
Cash position $927.14m
EPS (TTM) EPS $-2.24
P/E forward negative
Short interest 21.91%
Show more

Is Structure Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Structure Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Structure Therapeutics forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Structure Therapeutics forecast:

Buy
100%

Financial data from Structure Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.52 1.52
-
-
-1.52 -1.52
-
-
- Selling and Administrative Expenses 39 39
-
-
- Research and Development Expense 80 80
-
-
-121 -121
-
-
- Depreciation and Amortization 1.52 1.52
-
-
EBIT (Operating Income) EBIT -123 -123
-
-
Net Profit -101 -101
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Structure Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Structure Therapeutics Stock News

Neutral
GlobeNewsWire
10 days ago
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief ...
Positive
24/7 Wall Street
15 days ago
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
Neutral
GlobeNewsWire
about one month ago
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry
More Structure Therapeutics News

Company Profile

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

Head office Cayman Islands
CEO Raymond Stevens
Employees 93
Founded 2019
Website www.structuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today